BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Porter RF, Szczesniak AM, Toguri JT, Gebremeskel S, Johnston B, Lehmann C, Fingerle J, Rothenhäusler B, Perret C, Rogers-Evans M, Kimbara A, Nettekoven M, Guba W, Grether U, Ullmer C, Kelly MEM. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis. Molecules 2019;24:E3338. [PMID: 31540271 DOI: 10.3390/molecules24183338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou J, Kamali K, Lafreniere JD, Lehmann C. Real-Time Imaging of Immune Modulation by Cannabinoids Using Intravital Fluorescence Microscopy. Cannabis Cannabinoid Res 2021;6:221-32. [PMID: 34042507 DOI: 10.1089/can.2020.0179] [Reference Citation Analysis]
2 Brennecke B, Gazzi T, Atz K, Fingerle J, Kuner P, Schindler T, Weck GD, Nazaré M, Grether U. Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010. Pharmaceutical Patent Analyst 2021;10:111-63. [DOI: 10.4155/ppa-2021-0002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother 2021;146:112505. [PMID: 34891121 DOI: 10.1016/j.biopha.2021.112505] [Reference Citation Analysis]
4 Mingle D, Ospanov M, Radwan MO, Ashpole N, Otsuka M, Ross SA, Walker L, Shilabin AG, Ibrahim MA. First In Class (S,E)-11-[2-(Arylmethylene)Hydrazono]-PBD Analogs As Selective CB2 Modulators Targeting Neurodegenerative Disorders. Med Chem Res 2021;30:98-108. [PMID: 33776384 DOI: 10.1007/s00044-020-02640-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]